OTS186935
CAS No. 2093400-18-9
OTS186935 ( OTS-186935 | OTS 186935 )
产品货号. M13285 CAS No. 2093400-18-9
OTS186935 (OTS-186935) 是一种有效的体内活性蛋白甲基转移酶 SUV39H2 抑制剂,IC50 为 6.49 nM。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ¥7857 | 有现货 |
|
| 50MG | ¥16038 | 有现货 |
|
| 100MG | ¥20250 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称OTS186935
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述OTS186935 (OTS-186935) 是一种有效的体内活性蛋白甲基转移酶 SUV39H2 抑制剂,IC50 为 6.49 nM。
-
产品描述OTS186935 (OTS-186935) is a potent, in vivo-active inhibitor of protein methyltransferase SUV39H2 with IC50 of 6.49 nM, inhibits A549 cell growth with IC50 of 0.67 uM; causes a significant growth inhibitory effect in mouse xenograft models using MDA-MB-231 breast cancer cells as well as A549 lung cancer cells, at 25 mg/kg once daily for 14 days yielded a TGI of 60.8%; attenuates the levels of H3K9me3 in A549 xenograft mouse model.
-
体外实验OTS186935 inhibits A549 cell growth with an IC50 of 0.67 μM.
-
体内实验OTS186935 (10 mg/kg or 25 mg/kg; intravenously; once daily for 14 days) exhibits growth suppressive effects in human cancer cell line derived xenograft models. Animal Model:Female NOD.CB17-Prkdcscid/J mice(bearing MDA-MB-231 cells )Dosage:10 mg/kg Administration:Intravenously; once daily for 14 days Result:Tumor growth inhibition of 42.6% on day 14.Animal Model:Female BALB/cAJcl-nu/nu mice (bearing A549 cells)Dosage:25 mg/kg Administration:Intravenously; once daily for 14 days Result:Yielded a tumor growth inhibition of 60.8% without significant body weight loss or toxicity.
-
同义词OTS-186935 | OTS 186935
-
通路Chromatin/Epigenetic
-
靶点HMTase
-
受体HMTase
-
研究领域——
-
适应症——
化学信息
-
CAS Number2093400-18-9
-
分子量463.966
-
分子式C25H26ClN5O2
-
纯度>98% (HPLC)
-
溶解度——
-
SMILESCOC1=CC(=C(C=C1C2=CN3C=CC(=CC3=N2)N4CCC(C4)NCC5=CC=NC=C5)Cl)OC
-
化学全称(S)-1-(2-(5-chloro-2,4-dimethoxyphenyl)imidazo[1,2-a]pyridin-7-yl)-N-(pyridin-4-ylmethyl)pyrrolidin-3-amine
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Vougiouklakis T, et al. Oncotarget. 2018 Aug 7;9(61):31820-31831.
021-51111890
购物车()
sales@molnova.cn

